评估饮食对溃疡性结肠炎患者晚期治疗应答辅助作用的先导性随机对照试验
本研究纳入32例开始晚期治疗的活動性溃疡性结肠炎患者,随机分为低热量植物性模拟禁食饮食联合治疗组或对照饮食联合治疗组。意向性分析显示,第8周临床应答率在低热量植物性饮食组为57%(14例中8例),对照组为35%(17例中6例),差异无统计学意义(P=0.11)。低热量植物性饮食组在临床改善、激素减量及血清淀粉样蛋白A降低方面优于对照组,但研究因COVID-19提前终止且样本量有限。
要点
- 低热量植物性模拟禁食饮食未显著提高第8周临床应答率(57% vs 35%,P=0.11)。
- 低热量植物性饮食组连续SCCAI改善优于对照组(P=0.039),并有助于激素减量及降低血清淀粉样蛋白A。
- 研究因COVID-19提前终止,样本量小,需更大规模研究验证。
核心结论
- 低热量植物性饮食未改善溃疡性结肠炎患者对药物的临床应答,但带来了临床改善、激素减量及血清淀粉样蛋白A降低。
- 由于样本量有限,需要更大规模的研究。
研究设计与样本
- 先导性随机对照试验,计划纳入60例患者,但因COVID-19提前终止。
- 共纳入32例开始晚期治疗的活動性溃疡性结肠炎成人患者,23例完成研究。
- 患者随机分为低热量植物性饮食联合治疗组或对照饮食联合治疗组;低热量植物性饮食第1天提供1090千卡,第2-5天提供725千卡,共两个5天周期。
主要发现
- 意向性分析中,第8周临床应答(SCCAI下降≥3)率在低热量植物性饮食组为57%(14例中8例),对照组为35%(17例中6例),P=0.11。
- 低热量植物性饮食组连续SCCAI的临床改善优于对照组(P=0.039)。
- 低热量植物性饮食组在SCCAI子评分(如便急感、幸福感)方面更好,血清淀粉样蛋白A降低,并实现激素减量。
- 平均C反应蛋白和粪便钙卫蛋白在低热量植物性饮食组下降更多,但结果无统计学显著性。
- 未发生与饮食相关的严重不良事件,无体重减轻。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 研究因COVID-19提前终止。
- 样本量有限。
- 需要更大规模的研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Diet may influence ulcerative colitis (UC), but its impact on medication response remains unclear. We examined whether two 5-day cycles of a low-calorie, plant-based (LC-PB), fasting-mimicking diet could improve UC response to medications in a controlled trial. METHODS: Adults with active UC starting advanced therapies were randomized to an LC-PB diet + therapy or a control diet + therapy. The LC-PB diet provided 1090 kcal on day 1 and 725 kcal on days 2-5. The Simple Clinical Colitis Activity Index (SCCAI) was assessed at baseline and week 8. The study, planned for 60 patients, ended early due to COVID-19. The primary endpoint was clinical response (week 8, SCCAI decrease ≥3). Secondary outcomes were clinical improvement (change in SCCAI from baseline), steroid tapering, C-reactive protein, serum amyloid A (SAA), and fecal calprotectin. RESULTS: Of 32 enrolled patients, 23 completed the study. In the intention-to-treat analysis, 57% (n = 8 of 14) in the LC-PB arm achieved clinical response by week 8 vs 35% (n = 6 of 17) in control arm (P = .11). Secondary analyses indicated greater clinical improvement, measured as continuous SCCAI, in the LC-PB group compared with the control group (P = .039). The LC-PB group had better SCCAI subscores (ie, urgency, well-being), had reductions in SAA, and were tapered off steroids compared with the control group. Mean C-reactive protein and fecal calprotectin decreased more in the LC-PB group, but results were not significant. There were no serious adverse events relating to the diet and no weight loss. CONCLUSIONS: The LC-PB diet did not improve clinical response to medications. However, it led to clinical improvement, steroid tapering, and reduced SAA. As results were limited by sample size, larger studies are needed.
引用
- Damas OM, Leo M, Colina N, et al. A Pilot Randomized Control Trial to Assess the Adjunctive Effect of Diet on Response to Advanced Therapies in Patients With Ulcerative Colitis. Clin Gastroenterol Hepatol. 2025. PMID: 40378983. doi:10.1016/j.cgh.2025.03.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。